The trial’s primary end point was overall response rate (ORR). At the 3-year mark, the ORR was 59%, with a CR rate of 41%; both rates were maintained from prior analyses, “demonstrating the stability ...

Karlitz is the senior medical officer of screening at Exact Sciences and holds a voluntary teaching position in the gastrointestinal division at the University of Colorado School of Medicine. He ...

Accessibility remains one of the largest barriers to translating academic best practices into a community oncology setting, according to several panelists at the Boston Regional Institute for ...

The 2026 International Stroke Conference (ISC), held February 4-6 in New Orleans, Louisiana, delivered potentially ...

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables.

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables. 259 Prospect Plains Rd, Bldg H Cranbury, NJ ...

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care equitably with smart wearables. Rising stroke rates in young adults highlight ...

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care ...

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care ...

New stroke breakthroughs spotlight faster treatment, factor XI prevention, better recovery, and the push to deliver care ...

Ashkan Shoamanesh, MD, discusses a secondary analysis of the efficacy and safety of the factor XIa inhibitor asundexian by underlying stroke etiology. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...